Hepatitis Monthly

Published by: Kowsar

How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?

Alireza Ghaemi 1 , Fourugh Azam Taleban 1 , Azita Hekmatdoost 1 , Alireza Rafiei 2 , Vahid Hosseini 3 , Zohreh Amiri 4 , Reza Homayounfar 4 and Hafez Fakheri 3 , *
Authors Information
1 Department of Clinical Nutrition and Dietetics, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Molecular and Cell Biology Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
4 Department of Basic Sciences, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: December 01, 2013, 13 (12); e15227
  • Published Online: December 7, 2013
  • Article Type: Research Article
  • Received: October 6, 2013
  • Revised: October 23, 2013
  • Accepted: November 17, 2013
  • DOI: 10.5812/hepatmon.15227

To Cite: Ghaemi A, Taleban F A, Hekmatdoost A, Rafiei A, Hosseini V, et al. How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?, Hepat Mon. 2013 ; 13(12):e15227. doi: 10.5812/hepatmon.15227.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Rev. 2004; 5(1): 27-42
  • 2. Mensink RP, Plat J, Schrauwen P. Diet and nonalcoholic fatty liver disease. Curr Opin lipidol. 2008; 19(1): 25
  • 3. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007; 86(2): 285
  • 4. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J hepatol. 2010; 53(2): 372-384
  • 5. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009; 49(1): 306-317
  • 6. Khedmat H, Taheri S. Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy. Hepat Mon. 2010; 11(2): 74-85
  • 7. Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-1395
  • 8. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterol. 2011; 140(1): 124-131
  • 9. B Lankarani K, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al. Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study. Hepat Mon. 2013; 13(5)
  • 10. Sotoudehmanesh R, Sotoudeh M, Ali-Asgari A, Abedi-Ardakani B, Tavangar SM, Khakinejad A, et al. Silent liver diseases in autopsies from forensic medicine of Tehran. Arch Iran Med. 2006; 9(4): 324-328
  • 11. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Kalhori AB, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18): 2867
  • 12. Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterol. 2008; 134(1): 85-94
  • 13. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res. 2009; 50
  • 14. Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, Ashtari S, Khedmat H, Amin M, et al. Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation. Hepat Mon. 2013; 13(5)[DOI]
  • 15. Duvnjak M, Tomasic V, Gomercic M, Smircic-Duvnjak L, Barsic N, Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol. 2009; 60: 57-66
  • 16. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51(1): 121-129
  • 17. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011; 17(29): 3377
  • 18. Assy N. Nutritional recommendations for patients with non-alcoholic fatty liver diseases. World J Gastroenterol. 2011; 17(29): 3375
  • 19. Elias MC, Parise ER, Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition. 2009; 26: 1094-99
  • 20. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators inflamm. 2009; 831670
  • 21. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004; 39(6): 1647-1654
  • 22. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004; 53(3): 413
  • 23. Aadahl M, Jorgensen T. Validation of a new self-report instrument for measuring physical activity. Med Sci Sports Exerc. 2003; 35(7): 1196-202[DOI][PubMed]
  • 24. Kelishadi R, Ardalan G, Gheiratmand R, Gouya MM, Razaghi EM, Delavari A, et al. Association of physical activity and dietary behaviours in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bulletin World Health Org. 2007; 85(1): 19-26
  • 25. Hřebíček J, Janout V, Malinčíková J, Horáková D, Čížek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metabol. 2002; 87(1): 144-144
  • 26. Merriam PA, Ma Y, Olendzki BC, Schneider KL, Li W, Ockene IS, et al. Design and methods for testing a simple dietary message to improve weight loss and dietary quality. BMC Med Res Methodol. 2009; 9(1): 87
  • 27. Lang HF, Chou CY, Sheu WH, Lin JY. Weight loss increased serum adiponectin but decreased lipid levels in obese subjects whose body mass index was lower than 30 kg/m(2). Nutr Res. 2011; 31(5): 378-86[DOI][PubMed]
  • 28. Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity. 2008; 16(6): 1355-1362
  • 29. Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009; 44(12): 1203-1208
  • 30. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009; 17(12): 2162-2168
  • 31. Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol. 2006; 12(36): 5813
  • 32. Uslan I, Acarturk G, Karaca E, Albayrak R, Yuksel S, Colbay M, et al. The effects of weight loss on normal transaminase levels in obese patients. American J Med Sci. 2007; 334(5): 327
  • 33. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005; 100(5): 1072-1081
  • 34. Rebollo A, Roglans N, Alegret M, Laguna JC. Way back for fructose and liver metabolism: Bench side to molecular insights. World J Gastroenterol. 2012; 18(45): 6552
  • 35. Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011; 54(6): 1224-1229
  • 36. Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obesity Surg. 2011; 21(4): 431-439
  • 37. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 2006; 281(17): 12093-12101
  • 38. Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M, Itoshima T, et al. Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol. 2010; 56(5): 271-278
  • 39. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008; 103(4): 1036-1042
  • 40. Wieckowska A, Papouchado BG, Li ZZ, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008; 103(6): 1372-1379
  • 41. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012; 52(1): 59-69
  • 42. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clinica Chimica Acta. 2011; 412(15): 1297-1305
  • 43. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008; 19(8): 491-504
  • 44. Madan K, Bhardwaj P, Thareja S, Gupta S, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006; 40(10): 930-935
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments